231 related articles for article (PubMed ID: 36438821)
1. A comprehensive comparison of medication strategies for platinum-sensitive recurrent ovarian cancer: A Bayesian network meta-analysis.
Liu Y; Huang Y; Li J; Wan S; Jiang N; Yang J; Chiampanichayakul S; Tima S; Anuchapreeda S; Wu J
Front Pharmacol; 2022; 13():1010626. PubMed ID: 36438821
[No Abstract] [Full Text] [Related]
2. Comparison of the efficacy and safety of first-line treatments for of advanced EGFR mutation-positive non-small-cell lung cancer in Asian populations: a systematic review and network meta-analysis.
Chen W; Miao J; Wang Y; Xing W; Xu X; Wu R
Front Pharmacol; 2023; 14():1212313. PubMed ID: 37484016
[No Abstract] [Full Text] [Related]
3. Combinational use of trabectedin and pegylated liposomal doxorubicin for recurrent ovarian cancer: a meta-analysis of phase III randomized controlled trials.
Li C; Qiao S; Kang M; Gao X; Li Z
Am J Transl Res; 2023; 15(12):6675-6689. PubMed ID: 38186978
[TBL] [Abstract][Full Text] [Related]
4. Treatment options for recurrent platinum-resistant ovarian cancer: A systematic review and Bayesian network meta-analysis based on RCTs.
Li J; Zou G; Wang W; Yin C; Yan H; Liu S
Front Oncol; 2023; 13():1114484. PubMed ID: 37114128
[TBL] [Abstract][Full Text] [Related]
5. Optimal chemotherapy treatment for women with recurrent ovarian cancer.
Fung-Kee-Fung M; Oliver T; Elit L; Oza A; Hirte HW; Bryson P
Curr Oncol; 2007 Oct; 14(5):195-208. PubMed ID: 17938703
[TBL] [Abstract][Full Text] [Related]
6. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the second-line treatments for patients with small cell lung cancer sensitive to previous platinum-based chemotherapy: A systematic review and Bayesian network analysis.
Shi H; Guo N; Zhao Z; Liu L; Ni T; Zhang J; Lu Y
Front Oncol; 2023; 13():1154685. PubMed ID: 37007093
[TBL] [Abstract][Full Text] [Related]
8. The impact of Pegylated liposomal doxorubicin in recurrent ovarian cancer: an updated meta-analysis of randomized clinical trials.
Li XR; Zhu Y; Zhang GN; Huang JM; Pei LX
J Ovarian Res; 2021 Mar; 14(1):42. PubMed ID: 33750444
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of nab-paclitaxel plus platinum in non-small cell lung cancer: a meta-analysis.
Tan T; Li S; Hu W; Yue T; Zeng Q; Zeng X; Chen X; Zhao X; Xiao T
Front Med (Lausanne); 2023; 10():1139248. PubMed ID: 37554498
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the efficacy and safety of third-line treatments for metastatic colorectal cancer: a systematic review and network meta-analysis.
Gao L; Tang L; Hu Z; Peng J; Li X; Liu B
Front Oncol; 2023; 13():1269203. PubMed ID: 37810981
[TBL] [Abstract][Full Text] [Related]
11. Pegylated liposomal doxorubicin for first-line treatment of epithelial ovarian cancer.
Lawrie TA; Rabbie R; Thoma C; Morrison J
Cochrane Database Syst Rev; 2013 Oct; 2013(10):CD010482. PubMed ID: 24142521
[TBL] [Abstract][Full Text] [Related]
12. Treatments for relapsed, BRCA-wild type, platinum-sensitive ovarian cancer: A systematic review and network meta-analysis.
Petrelli F; Rea CG; Solinas C; Ghidini A; Borgonovo K; Celotti A; Villa A; Luciani A; Lorusso D
Cancer Treat Rev; 2023 Jul; 118():102571. PubMed ID: 37201444
[TBL] [Abstract][Full Text] [Related]
13. A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancer.
Monk BJ; Herzog TJ; Wang G; Triantos S; Maul S; Knoblauch R; McGowan T; Shalaby WSW; Coleman RL
Gynecol Oncol; 2020 Mar; 156(3):535-544. PubMed ID: 31924332
[TBL] [Abstract][Full Text] [Related]
14. Comparison of First-Line Treatments for Patients With Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-analysis.
Zhou T; Zhang Z; Luo F; Zhao Y; Hou X; Liu T; Wang K; Zhao H; Huang Y; Zhang L
JAMA Netw Open; 2020 Oct; 3(10):e2015748. PubMed ID: 33074323
[TBL] [Abstract][Full Text] [Related]
15. Combination therapy for high-volume
Jian T; Zhan Y; Yu Y; Yu K; Hu R; Wang J; Lu J
Front Pharmacol; 2023; 14():1148021. PubMed ID: 37153773
[No Abstract] [Full Text] [Related]
16. Efficacy and safety of targeted therapeutics for patients with radioiodine-refractory differentiated thyroid cancer: Systematic review and network meta-analysis.
Ji X; Liang W; Lv G; Ding C; Lai H; Li L; Zeng Q; Lv B; Sheng L
Front Pharmacol; 2022; 13():933648. PubMed ID: 36091770
[No Abstract] [Full Text] [Related]
17. First-Line Systemic Treatment Strategies for Unresectable Hepatocellular Carcinoma: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials.
Liu W; Quan B; Lu S; Tang B; Li M; Chen R; Ren Z; Yin X
Front Oncol; 2021; 11():771045. PubMed ID: 35004289
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the Efficacy and Safety of PARP Inhibitors as a Monotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis.
Wang H; Wu M; Liu H; Zhou H; Zhao Y; Geng Y; Jiang B; Zhang K; Zhang B; Han Z; Du X
Front Oncol; 2021; 11():785102. PubMed ID: 34900739
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial.
Pfisterer J; Shannon CM; Baumann K; Rau J; Harter P; Joly F; Sehouli J; Canzler U; Schmalfeldt B; Dean AP; Hein A; Zeimet AG; Hanker LC; Petit T; Marmé F; El-Balat A; Glasspool R; de Gregorio N; Mahner S; Meniawy TM; Park-Simon TW; Mouret-Reynier MA; Costan C; Meier W; Reinthaller A; Goh JC; L'Haridon T; Baron Hay S; Kommoss S; du Bois A; Kurtz JE;
Lancet Oncol; 2020 May; 21(5):699-709. PubMed ID: 32305099
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab or PARP-Inhibitors Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis.
Bartoletti M; Pelizzari G; Gerratana L; Bortot L; Lombardi D; Nicoloso M; Scalone S; Giorda G; Baldassarre G; Sorio R; Puglisi F
Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32471250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
